Compounds and Compositions as Protein Kinase Inhibitors
    6.
    发明申请
    Compounds and Compositions as Protein Kinase Inhibitors 失效
    化合物和组合物作为蛋白激酶抑制剂

    公开(公告)号:US20080287432A1

    公开(公告)日:2008-11-20

    申请号:US12063550

    申请日:2006-08-15

    CPC分类号: C07D471/14 C07D495/14

    摘要: The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases.

    摘要翻译: 本发明提供了一类新颖的式I化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及AbI异常活化的疾病或病症, Bcr-AbI,Aurora-A,SGK,Tie-2,Trk-B,FGFR3,c-kit,b-RAF,c-RAF,DYRK2,Fms,Fyn和PDGFRα和PDGFRβ激酶。

    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS
    9.
    发明申请
    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS 失效
    作为蛋白激酶抑制剂的化合物和组合物

    公开(公告)号:US20100048552A1

    公开(公告)日:2010-02-25

    申请号:US12299687

    申请日:2007-05-11

    CPC分类号: C07D471/14

    摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

    摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,Bcr-Abl异常活化的疾病或病症 ,Bcr-Abl(T315I),ALK,BLK,BMX,BRK,C-kit,c-RAF,CSK,c-SRC,EGFR,Fes,FGFR3,Flt3,Fms,Fyn,IGF-1R,IR,JAK( 2),JAK(3),KDR,Lck,NLK,p70S6K,PDGFRα,Ros,SAPK2α,SGK,SIK,Syk,Tie2和TrkB激酶。

    Compounds and compositions as protein kinase inhibitors
    10.
    发明授权
    Compounds and compositions as protein kinase inhibitors 失效
    化合物和组合物作为蛋白激酶抑制剂

    公开(公告)号:US07589101B2

    公开(公告)日:2009-09-15

    申请号:US12063550

    申请日:2006-08-15

    CPC分类号: C07D471/14 C07D495/14

    摘要: The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases.

    摘要翻译: 本发明提供了一类新颖的式I化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及AbI异常活化的疾病或病症, Bcr-AbI,Aurora-A,SGK,Tie-2,Trk-B,FGFR3,c-kit,b-RAF,c-RAF,DYRK2,Fms,Fyn和PDGFRα和PDGFRβ激酶。